Six-fraction RT produced rapid symptom relief in tumors involving the brachial plexus
A 33 Gy/6-fraction boost regimen improved plexus-related symptoms in 84% of evaluable patients and achieved 74% freedom from local progression at one year.
Tag
ultrahypofractionation
Single-fraction SBRT has strongest curative evidence in peripheral lung and kidney tumors
ESTRO’s review supports selected single-fraction SBRT applications while highlighting major evidence and toxicity gaps in abdominal tumors.
Five-fraction breast RT is established for WBI and APBI, while RNI evidence matures
Five-fraction RT is well supported for selected whole- and partial-breast treatment, while regional nodal and postmastectomy evidence remains less mature.
Breast edema appeared after the first fraction in 5-fraction radiotherapy
CBCT detected breast edema in 37.1% during 26 Gy in five fractions, usually immediately after the first treatment.
Single-fraction lung SBRT achieved 100% estimated one-year local control in selected patients
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
Six-fraction chemoradiation worsened survival in newly diagnosed glioblastoma
Six-fraction chemoradiation shortened median survival from 21 to 13 months and substantially increased radiation necrosis compared with standard treatment.
Five-fraction prostate radiotherapy showed low severe toxicity in men aged 75 or older
Five-fraction prostate radiotherapy achieved 82% three-year biochemical control with very few grade 3 toxicities in men aged 75 or older.
Five-fraction prostate radiotherapy reduced estimated carbon emissions by 59%
Five-fraction prostate radiotherapy produced 58.6% lower estimated carbon emissions than a 26-fraction schedule, mainly by reducing patient travel.
Five-fraction whole-breast irradiation showed low short-term toxicity across 28 Italian centres
Whole-breast irradiation with 26 Gy in five fractions produced mainly grade 1 toxicity in 2,036 patients, including those receiving a boost.
DEGRO supports ultrahypofractionation for localized prostate cancer but flags higher late urinary toxicity
DEGRO supports ultrahypofractionation for low- to intermediate-risk prostate cancer, with comparable control but increased late genitourinary toxicity in selected patients.
Twice-weekly 28 Gy whole-breast irradiation showed low toxicity in early breast cancer
Twice-weekly 28 Gy in 5 fractions produced no grade 3 or higher toxicity and 98.8% excellent-to-good cosmesis at 1 year.
Single-fraction prostate radiotherapy achieved 92.9% three-year biochemical relapse-free survival
A single 19-Gy fraction achieved 92.9% three-year biochemical relapse-free survival with limited grade 2 gastrointestinal and genitourinary toxicity.